OncoMatch/Clinical Trials/NCT07455019
A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer
Is NCT07455019 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies The treatment group using pembrolizumab combined with anlotinib and radiotherapy and chemotherapy for esophageal cancer.
Treatment: The treatment group using pembrolizumab combined with anlotinib and radiotherapy and chemotherapy — This study aims to evaluate the efficacy and safety of bemosubabimab combined with anlotinib and radiotherapy and chemotherapy in the treatment of patients with oligometastatic esophageal cancer. The study adopted a single-center, single-arm trial design. Eligible patients with oligometastatic esophageal squamous cell carcinoma were treated with bemosubaiabant, anlotinib, and combined radiotherapy and chemotherapy for 4 to 6 cycles, followed by maintenance treatment with bemosubaiabant and anlotinib. During the study period, the subjects were not allowed to receive any other anti-tumor treatments. If the dose of anlotinib hydrochloride was adjusted due to safety events for the subjects, the anlotinib hydrochloride would be dispensed according to the investigator's prescription.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: PD-1/PD-L1/CTLA-4 antibody
Have received PD-1/PD-L1/CTLA-4 antibody or anti-angiogenic drugs (such as sunitinib, sorafenib, regorafenib, bevacizumab, imatinib, apatinib, etc.) in the past
Cannot have received: anti-angiogenic drug (sunitinib, sorafenib, regorafenib, bevacizumab, imatinib, apatinib)
Have received PD-1/PD-L1/CTLA-4 antibody or anti-angiogenic drugs (such as sunitinib, sorafenib, regorafenib, bevacizumab, imatinib, apatinib, etc.) in the past
Cannot have received: systematic anti-tumor chemotherapy
received systematic anti-tumor chemotherapy, radiotherapy or other anti-tumor treatments
Cannot have received: radiotherapy
received systematic anti-tumor chemotherapy, radiotherapy or other anti-tumor treatments
Cannot have received: other anti-tumor treatments
received systematic anti-tumor chemotherapy, radiotherapy or other anti-tumor treatments
Lab requirements
Blood counts
Adequate organ and bone marrow functions
Kidney function
Adequate organ and bone marrow functions; exclusion: renal failure requiring hemodialysis or peritoneal dialysis
Liver function
Adequate organ and bone marrow functions; exclusion: liver cirrhosis, decompensated liver disease, active hepatitis or chronic hepatitis (hepatitis virus load > 1000 IU/ml) requiring antiviral treatment
Cardiac function
Exclusion: grade II or above myocardial ischemia or myocardial infarction, arrhythmia (including QTc, male ≥ 450 ms; female ≥ 470 ms) and ≥ 2 grade congestive heart failure (NYHA classification)
Adequate organ and bone marrow functions; see exclusion criteria for details
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify